secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alpha Teknova, Inc. (TKNO)
CIK:        0001850902
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096188
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alpha Teknova Q2 revenue $9.6M, down 17% YoY; reaffirms FY2024 guidance $35-38M
-------------------------------------------------------------------------------

- Revenue $9.6M, down 17% YoY but up 3% sequentially; Lab Essentials flat, Clinical Solutions down 57%.
- Net loss $5.4M ($0.13/share) vs $7.2M prior year; Adjusted EBITDA negative $2.6M.
- Gross margin fell to 29.2% from 43.9% due to lower Clinical Solutions revenue and higher overhead.
- Raised $15.4M equity in July 2024; cash $18.6M, debt $12.1M; confirms free cash outflow <$18M for FY.
- Clinical customers up 26% to 43; launched Express-Tek and RUO+ offerings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850902/000095017024096188/0000950170-24-096188-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850902/000095017024096188/tkno-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096188

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer